Tocqueville Asset Management L.P. Medicenna Therapeutics Corp. Transaction History

Tocqueville Asset Management L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$0.4 - $0.68 $15,400 - $26,180	-38,500 Reduced 32.77%	79,000 $36,000
Q3 2022 Nov 10, 2022	BUY	$0.83 - $1.78 $3,735 - $8,010	4,500 Added 3.98%	117,500 $97,000
Q2 2022 Aug 12, 2022	BUY	$0.79 - $1.32 $19,750 - $33,000	25,000 Added 28.41%	113,000 $132,000
Q4 2021 Feb 14, 2022	SELL	$1.53 - $2.85 $7,650 - $14,250	-5,000 Reduced 5.38%	88,000 $143,000
Q3 2021 Nov 15, 2021	SELL	$1.91 - $3.05 $8,977 - $14,335	-4,700 Reduced 4.81%	93,000 $258,000
Q2 2021 Aug 16, 2021	BUY	$2.97 - $4.28 $15,147 - $21,828	5,100 Added 5.51%	97,700 $294,000
Q4 2020 Feb 16, 2021	BUY	$3.7 - $5.97 $102,490 - $165,369	27,700 Added 42.68%	92,600 $433,000
Q3 2020 Nov 16, 2020	BUY	$3.55 - $4.67 $35,500 - $46,700	10,000 Added 18.21%	64,900 $269,000
Q2 2020 Aug 12, 2020	BUY	$2.34 - $5.11 $128,465 - $280,539	54,900 New	54,900 $199,000

863K

Ticker MDNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,637,504
Market Cap $21.6M
Description
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as...

Get notified when there are updates to the investment portfolio of Tocqueville Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on Tocqueville Asset Management L.P. with notifications on news.